Home/ Stocks/ SGMO

Sangamo Therapeutics, Inc. Common Stock

SGMO XNAS

$0.35 +0.03 (+7.91%) ▲ 15-min delayed

Open

$0.33

High

$0.36

Low

$0.33

Volume

3.84M

Market Cap

$124.51M

About Sangamo Therapeutics, Inc. Common Stock

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 183 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$581.0K	$-34,930,000	$-0.11
Q2 2025	$18.31M	$-19,986,000	$-0.08
Q1 2025	$6.44M	$-30,597,000	$-0.14
FY 2024	$57.80M	$-97,941,000	$-0.49

Related Market News

No specific coverage for SGMO yet. Check out our latest market news or earnings calendar.

Get SGMO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Sangamo Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.